Bone Metastases
Project summary
The EORTC QLQ-BM22 is a 22-item questionnaire developed to assess health-related quality of life (HRQoL) in patients with bone metastases. It is designed to complement the EORTC QLQ-C30 and comprises four domains: painful sites, pain characteristics, functional interference, and psychosocial aspects.
The QLQ-BM22 has completed all four phases of EORTC module development and is fully validated. International Phase 4 field testing involving 400 patients across seven countries confirmed its reliability, validity, cross-cultural applicability, and responsiveness. The validation findings were published in Cancer in 2012 (Chow et al., doi:10.1002/cncr.26410).
We are also undertaking an update of the QLQ-BM22 to better capture HRQoL issues relevant to contemporary treatments and the evolving needs of patients with bone metastases.
We have recently completed Phases 1 and 2 of the update, resulting in a provisional 45-item module (QLQ-BM45), comprising the original 22 items and 23 additional items. The Phase 1–2 report is being finalised for EORTC QLG approval (pending final review of a requested minor revision), and we plan to proceed to Phase 3 pre-testing, followed by Phase 4 international validation.
Related publications we published for the phase1–2 of BM22 update: https://ddei5-0-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fwww.thelancet.com%2fretrieve%2fpii%2fS258953702600218X&umid=8226813A-5E48-D306-9AFB-71555C07DA4B&auth=146d7ac271cb81a53802810e8fcad10467d2d32a-3de24d5f1e5f0459a46b028c109f824df17b5450